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Aims Biomarkers have proven their ability in the evaluation of cardiopulmonary diseases. We investigated the utility of con-
centrations of the biomarker procalcitonin (PCT) alone and with clinical variables for the diagnosis of pneumonia in
patients presenting to emergency departments (EDs) with a chief complaint of shortness of breath.
Methods
and results
The BACH trial was a prospective, international, study of 1641 patients presenting to EDs with dyspnoea. Blood
samples were analysed for PCT and other biomarkers. Relevant clinical data were also captured. Patient outcomes
were assessed at 90 days. The diagnosis of pneumonia was made using strictly validated guidelines. A model using
PCT was more accurate [area under the curve (AUC) 72.3%] than any other individual clinical variable for the diag-
nosis of pneumonia in all patients, in those with obstructive lung disease, and in those with acute heart failure (AHF).
Combining physician estimates of the probability of pneumonia with PCT values increased the accuracy to .86% for
the diagnosis of pneumonia in all patients. Patients with a diagnosis of AHF and an elevated PCT concentration
(.0.21 ng/mL) had a worse outcome if not treated with antibiotics (P ¼ 0.046), while patients with low PCT
values (,0.05 ng/mL) had a better outcome if they did not receive antibiotic therapy (P ¼ 0.049).
Conclusion Procalcitonin may aid in the diagnosis of pneumonia, particularly in cases with high diagnostic uncertainty. Importantly,
PCT may aid in the decision to administer antibiotic therapy to patients presenting with AHF in which clinical uncer-
tainty exists regarding a superimposed bacterial infection.
Trial registration: NCT00537628
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The chief complaint of shortness of breath in patients presenting
with suspected pneumonia requires a rapid accurate assessment
so that early antibiotic therapy can be initiated and appropriate
additional management implemented.
1,2 The diagnosis of pneumo-
nia can be difﬁcult in patients with pre-existing parenchymal lung
disease because of baseline abnormal chest imaging, or in those
presenting with an acute exacerbation of obstructive lung disease
(AECOPD), bronchitis, or viral syndrome, because of overlapping
symptoms. Detecting superimposed pneumonia in patients pre-
senting with acute heart failure (AHF) is additionally difﬁcult
because of the non-speciﬁc nature of chest X-ray abnormalities
in the setting of cardiogenic pulmonary oedema. Unfortunately,
misdiagnoses may result in delayed or erroneous treatment poten-
tially increasing adverse outcomes.
3,4 Procalcitonin (PCT) expres-
sion in parenchymal tissue is induced by bacterial infection. PCT
is a diagnostic marker of severe bacterial infections. While PCT
release is not organ speciﬁc, concentrations have been successfully
used to diagnose and guide antibiotic therapy (initiation and cessa-
tion) in lower respiratory tract infections, pneumonia, and sepsis.
5,6
However, PCT has never been extensively studied for its ability to
identify pneumonia or bacterial infection in the setting of AHF. We
hypothesized that in patients presenting with a chief compliant of
shortness of breath, PCT can signiﬁcantly enhance the clinician’s
ability to diagnose pneumonia, whether occurring in isolation, or
in the setting of AHF or of AECOPD. We also evaluated the asso-
ciation between PCT concentration, antibiotic treatment, and
outcome in patients with a primary diagnosis of AHF, reasoning
that overlapping symptoms of cough, shortness of breath, and ab-
normal chest imaging make this group uniquely challenging for clin-
icians with regards to the diagnosis of superimposed pneumonia,
possibly leading to inappropriate antibiotic utilization.
Methods
The BACH (Biomarkers in Acute Heart Failure) trial was a prospective,
15-centre international study of 1641 patients presenting to the emer-
gency department (ED) with a chief complaint of dyspnoea. All sites
received local Institutional Review Board approval. The primary
results have been reported elsewhere.
7
Study population
A total of 1641 patients reporting shortness of breath upon presenta-
tion to the ED were enrolled from March 2007 to February 2008.
Patients were excluded if they were under 18 years of age, unable
to provide consent, had an acute ST-elevation myocardial infarction,
were receiving haemodialysis, or had renal failure. The emergency phy-
sicians (EPs), blinded to the results of the investigational markers,
assessed the patients enrolled in the study for the diagnosis of AHF
or pneumonia using two separate visual analogue scales (VASs) and
assigned a value of 0–100% clinical diagnostic certainty.
Conﬁrmation of diagnosis
The gold standards for the diagnoses were determined by two cardi-
ologists who independently reviewed all medical records and classiﬁed
the likely diagnosis as heart failure (HF), pneumonia, a combination of
both, or another diagnosis. Both were blinded to the other’s
assessments, investigational markers, and the EP’s diagnosis. In the
event of disagreement that could not be settled, a third adjudicator
was used. In cases of suspected pneumonia, diagnosed using modiﬁed
criteria from Fine et al. and Leroy et al.,
8,9 a single pulmonologist,
blinded only to biomarker values, reviewed each case. All cases of
pneumonia were required to have a new inﬁltrate on chest imaging
in combination with microbiological proof of infection, or more than
one of the major criteria. In cases of equivocal chest imaging (intersti-
tial pattern, effusions), at least two major criteria were necessary.
Community-acquired and healthcare-associated pneumonias were
both recorded as pneumonia.
Biomarker assessment
Procalcitonin and other biomarkers were quantiﬁed with an auto-
mated sandwich immunoassay using TRACE technology described pre-
viously.
7 The PCT-sensitive KRYPTOR assay has a detection limit of
0.02 ng/mL and a functional assay sensitivity of 0.06 ng/mL. The inter-
assay coefﬁcient of variation for concentrations .0.3 ng/mL is ,6%.
Samples were processed by personnel blinded from any patient data.
White blood cell count (WBC) and C-reactive protein, if measured
as part of the clinician’s usual diagnostic workup, were potentially
known to the clinician at the time of VAS determination.
Statistical analysis
Values are expressed as means and standard deviations, medians and
interquartile ranges (IQR), or counts and percentages, as appropriate.
Patients with and without pneumonia were compared with independ-
ent samples t-tests or Fisher’s exact tests, as appropriate. Variables
were log-transformed if appropriate.
Logistic regression was used to evaluate PCT for the diagnosis of
pneumonia, for both uni- and multivariable analysis. To demonstrate
independence from clinical variables, the added value of PCT on top
of (i) a multivariable model with the seven most signiﬁcant univariate
variables and (ii) the physician-estimated probability of pneumonia
was evaluated based on the likelihood ratio x
2 test for nested
models. The concordance index [C index or area under the curve
(AUC)] is given as an effect measure for uni- and multivariable
models. For multivariable models, a bootstrap-corrected version of
the C index/AUC is given. For continuous variables, odds ratios
(ORs) were standardized to describe the OR for a change of one
IQR. The 95% conﬁdence intervals (CIs) for risk factors and signiﬁ-
cance levels for x
2 are given.
10 Net reclassiﬁcation improvements
(NRIs) were calculated for adding PCT based on categories which rep-
resent approximately the 15th and 85th percentile of the predicted
probability for the model excluding PCT.
11 Receiver operating charac-
teristic (ROC) curves were constructed to assess the sensitivity and
speciﬁcity of PCT and multivariable models to compare their ability
to predict pneumonia.
Cox proportional hazards regression was used to analyse the asso-
ciation of risk factors with survival in uni- and multivariable analyses.
The C index is given as an effect measure. Survival curves plotted by
the Kaplan–Meier method were used for illustration. For categorical
variables, log-rank test P-values are given. To account for systematic
differences between patients with and without antibiotic treatment,
survival rates were adjusted for covariates.
10
All analyses utilized a two-sided P-value of 0.05 for signiﬁcance.
All statistical analyses were performed using R version 2.5.1
(http://www.r-project.org) and Statistical Package for the Social
Sciences (SPSS) version 16.0 (SPSS Chicago, IL, USA).
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A total of 1641 patients were evaluated in the ED for shortness of
breath, of which 6.8% (112) received a primary diagnosis of pneu-
monia, 34.6% (568) AHF, 12.2% (201) chronic obstructive pulmon-
ary disease (COPD) exacerbation, 7.0% (130) asthma
exacerbation, 6.5% (106) chest pain, 3.7% (61) bronchitis, 3.4%
(55) arrhythmia, 2.4% (39) acute coronary syndrome, 2.3% (38)
pulmonary embolism, 1.6% (27) inﬂuenza, and 18.5% (304) other
diseases. A total of 155 patients (9.4%) with a primary or second-
ary diagnosis of pneumonia (112 as primary, and 43 as secondary)
were combined. There were 407 patients (24.8%) diagnosed with
an AECOPD (271 with COPD and 136 with asthma).
Patient characteristics in the pneumonia group and the non-
pneumonia group are shown in Table 1. Patients with pneumonia
were signiﬁcantly more likely to have a past medical history of
COPD and pneumonia, and a recent history of cough and night
sweats. A past medical history of HF, coronary artery disease, myo-
cardial infarction, and angioplasty was signiﬁcantly more common
in patients without pneumonia. PCT levels were obtained for
99.4% of all patients. PCT ranged from 0.02 to 349 ng/mL, with a
median of 0.07 ng/mL and an IQR from 0.05 to 0.13 ng/mL.
In healthy subjects, PCT plasma concentrations are typically
,0.05 ng/mL.
12
Procalcitonin for the diagnosis of
pneumonia
Overall, 155 (9.4%) patients had a primary or secondary diagnosis
of pneumonia. Twenty-nine of these had concurrent AHF and 17
had a concurrent AECOPD (13), asthma (2), or bronchitis (2).
For patients with pneumonia, median PCT concentration was
0.18 ng/mL (IQR 0.07–0.58), and for patients without pneumonia
PCT was 0.07 ng/mL (IQR 0.05–0.12). In total, 203 patients
were on antibiotics upon entry. Their median PCT concentration
was 0.08 ng/mL (IQR 0.05–0.20). A univariate logistic regression
model for predicting the diagnosis of pneumonia was highly signiﬁ-
cant for PCT (x
2 106.8, P , 0.0001, AUC 0.723). PCT predicted
pneumonia equally well in the subgroup of patients with a
history of lung disease (asthma or COPD) (AUC 0.713) and in
patients presenting with an AECOPD or bronchitis (AUC 0.715),
but slightly less in patients with concurrent AHF (AUC 0.641).
Multivariable analysis combining PCT values with clinical signs
(Table 2) demonstrated that PCT contributed signiﬁcantly to the
prediction of pneumonia (P , 0.0001), adding independent infor-
mation to clinical signs and increasing the AUC from 0.841 to
0.863 (x
2 for adding PCT to the model 37.5, df ¼ 1, P , 0.0001).
Bootstrap-corrected AUCs were 0.834 for the model with clinical
signs only and 0.857 for the model including PCT (P , 0.0001).
Within this model, PCT was one of the strongest markers,
together with temperature and recent history of cough. PCT
was associated with a net reclassiﬁcation improvement of 5.0%
(95% CI 4.0–6.2%), based on risk categories representing approxi-
mately the 15th and 85th percentile of the predicted probability
for the model including clinical signs only. Overall, the model in-
cluding PCT moved 2.9% of pneumonia into a higher probability
category, and 5.2% of non-pneumonia into a lower probability
category.
Similarly, in a model incorporating both log-transformed PCT
and physician-estimated probability, both variables contributed sig-
niﬁcantly to the prediction of pneumonia (P , 0.0001). PCT
increased the AUC from 0.850 to 0.864 (x
2 for adding PCT to
the VAS 28.2, df ¼ 1, P , 0.0001). The bootstrap-corrected
AUC for the combined model including PCT was 0.863 (P ,
0.0001), with an NRI of 5.0% (95% CI 4.0–6.2%). The model in-
cluding PCT moved 2.1% of pneumonia into a higher probability
category, and 5.3% of non-pneumonia into a lower probability cat-
egory. Figure 1 illustrates the predictive performance for PCT
alone, the multivariable model including clinical signs, and the com-
bined model including PCT using ROC curve analysis.
Chest X-ray was performed in 1445 patients (88%), of which
144 (10%) had deﬁnitive ﬁndings consistent with pneumonia [sen-
sitivity and speciﬁcity 64.0% (95% CI 55.6–71.6%) and 95.7% (95%
CI 94.4–96.6%), respectively]. PCT signiﬁcantly added to the diag-
nostic value of the chest X-ray for the diagnosis of pneumonia,
improving the AUC from 0.798 (chest X-ray alone) to 0.864
(chest X-ray and PCT) (P , 0.0001)). Importantly, PCT remained
signiﬁcant when the chest X-ray is included in the multivariable
clinical signs model (P , 0.0001).
Total leucocyte count (WBC) was a moderate predictor for
pneumonia, with an AUC of 0.69 (data not shown). This is consist-
ent with ﬁndings from previous research.
13 PCT added signiﬁcantly
to the predictive value of WBC (added x
2 74.5, P , 0.0001) indi-
cating that PCT was better than and independent from WBC for
predicting pneumonia. Adding (log-transformed) WBC to the mul-
tivariable model in Table 2 does not affect the results (PCT
remained signiﬁcant, P , 0.0001). Due to the missing values in
WBC, the available patients for the multivariable model were,
however, signiﬁcantly reduced.
Decreasing clinical uncertainty in difﬁcult
to diagnose pneumonia cases
At presentation, doctors were uncertain (deﬁned as probability
estimates between 21% and 80%) about the presence of pneumo-
nia in 30% of patients (n ¼ 499). In the 208 patients who presented
with a PCT value .0.25 ng/mL, a concentration that predicts
bacterial infection,
12 the EP-estimated probability of pneumonia
was high (.80%) in only 15% of cases. The distributions of the
physician probability estimates are illustrated in Figure 2. This
ﬁgure also demonstrates how the uncertain category (labelled
‘Medium’) would be reduced by 82% if physician estimates were
combined with a model ruling out pneumonia when PCT values
were ,0.25 ng/mL.
Procalcitonin and the decision to give
antibiotics to patients presenting with
acute heart failure
PCT was signiﬁcantly associated with 90-day all-cause mortality
f o rp a t i e n t sd i a g n o s e dw i t hA H F( P ¼ 0.0024). Figure 3 illustrates
this relationship in a Kaplan–Meier plot of PCT quintiles.
Patients in the ﬁrst quintile (PCT , 0.05 ng/mL) had a 90-day
survival rate of 92.0%, which fell to 80.5% (hazard ratio 2.6)
f o rp a t i e n t si nt h eﬁ f t hq u i n t i l e( P C T. 0.21 ng/mL). One-ﬁfth
(20.8%) of these patients diagnosed with AHF were also
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Table 1 Patient characteristics grouped by the presence or absence of pneumonia
Variables N Non-pneumonia (n 5 1486) Pneumonia (n 5 155) P-value
Demographics
Age (years) 1641 63.5+17.0 66.3+15.8 0.0517
Male gender 1641 770 (51.8) 89 (57.4) 0.2049
Race 1626 0.0005
White 966 (65.6) 124 (80.5)
Black 451 (30.6) 25 (16.2)
Other 55 (3.7) 5 (3.2)
Recent history
Smoking 1593 420 (29.1) 49 (32.9) 0.3456
Wheezing 1543 430 (30.6) 38 (27.3) 0.4409
Cough 1603 811 (54.6) 137 (88.4) ,0.0001
Weight gain 1438 235 (17.9) 14 (10.9) 0.0497
Night sweats 1495 284 (20.9) 40 (29.2) 0.0294
Orthopnoea 1536 625 (44.8) 64 (45.7) 0.8587
Dyspnoea at rest 1605 719 (49.6) 76 (49.4) 1.0000
Exam variables
Heart rate (b.p.m.) 1641 89.8+23.6 101.6+22.8 ,0.0001
Systolic BP (mmHg) 1641 140.6+30.4 133.5+31.3 0.0055
Diastolic BP (mmHg) 1641 80.8+18.2 74.9+19.9 0.0002
BMI (kg/m
2) 1399 29.4+8.9 27.0+7.6 0.0034
Temperature (8C) 1576 36.70+0.63 37.41+1.00 ,0.0001
Pulse oximetry (%) 1609 95.3+5.3 93.2+5.3 ,0.0001
Rales 1624 452 (30.8) 72 (46.5) 0.0001
S3 1580 43 (3) 1 (0.7) 0.1175
Murmur 1604 226 (15.5) 28 (18.7) 0.3467
Elevated JVP 1539 256 (18.4) 15 (10.1) 0.0121
Oedema 1615 548 (37.5) 40 (26.1) 0.0060
Ascites 1579 38 (2.7) 3 (2) 0.7917
Wheezing 1619 397 (27.1) 55 (35.5) 0.0304
History variables
Arrhythmia 1555 365 (25.9) 40 (27.2) 0.7671
Asthma 1594 289 (20.0) 29 (19.2) 0.9148
CRI 1584 222 (15.5) 24 (16.2) 0.8117
HF 1597 531 (36.7) 38 (25.5) 0.0069
CAD 1587 469 (32.6) 34 (23) 0.0159
COPD 1594 409 (28.4) 62 (40.8) 0.002
DM 1621 427 (29.1) 35 (22.7) 0.1104
Hyperlipidaemia 1549 529 (37.5) 41 (29.5) 0.0654
Hypertension 1614 987 (67.5) 93 (61.6) 0.1470
MI 1584 282 (19.7) 18 (11.9) 0.0214
Pneumonia 1536 196 (13.2) 64 (41.3) 0.0005
Pulmonary embolism 1604 75 (5.2) 10 (6.5) 0.4482
CABG 1615 141 (9.7) 17 (11.0) 0.5687
Angioplasty/stent 1602 194 (13.4) 10 (6.6) 0.0147
Stroke/CVA 1608 151 (10.4) 14 (9.0) 0.6774
Pacemaker/ICD 1616 144 (9.9) 18 (11.6) 0.4820
Prosthetic valve 1612 37 (2.5) 6 (3.9) 0.2935
Outpatient medications (known)
Asprin 1616 526 (36.0) 48 (31.4) 0.2870
Clopidogrel 1617 124 (8.5) 7 (4.6) 0.1175
Warfarin 1615 232 (15.9) 25 (16.3) 0.9075
Continued
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the time of presentation), while only 5.1% (29) of those were
ultimately diagnosed with pneumonia, suggesting the possibility
of unnecessary antibiotic therapy. Additionally, in patients not
treated with antibiotics on presentation, PCT predicted the pos-
sible need for antibiotic therapy during follow-up, representing a
potential missed opportunity to treat: 33.0% of patients with
PCT . with 17.3% of patients with PCT values ,0.21 ng/mL
(P , 0.01). Notably, of the 117 patients with PCT concentra-
tions suggesting signiﬁcant bacterial infection (.0.5 ng/mL), 38
(32%) did not receive antibiotic therapy. In this group, half
were diagnosed with AHF, highlighting the difﬁculty of diagnos-
ing superimposed bacterial infection in patients presenting
with AHF.
...............................................................................................................................................................................
Table1 Continued
Variables N Non-pneumonia (n 5 1486) Pneumonia (n 5 155) P-value
Beta-blockers 1613 580 (39.7) 47 (31.1) 0.0436
ACE inhibitors or ARBs 1616 622 (42.5) 58 (37.9) 0.3019
Calcium channel blockers 1614 329 (22.5) 40 (26.1) 0.3124
Statins 1617 485 (33.1) 32 (20.9) 0.0019
Diuretics 1618 713 (48.7) 61 (39.9) 0.0412
Digoxin 1617 111 (7.6) 9 (5.9) 0.5196
Aldosterone inhibitor 1615 139 (9.5) 10 (6.6) 0.3016
Anti-arrhythmics 1616 84 (5.7) 8 (5.3) 1.000
Nebulizer/inhaler 1613 497 (34.0) 64 (42.1) 0.0492
Steroids 1582 341 (23.8) 50 (33.3) 0.0127
Antibiotics 1614 161 (11.0) 42 (27.6) ,0.0001
Smoking cessation therapy 1577 27 (1.9) 1 (0.7) 0.5111
Other 1593 941 (65.2) 89 (59.3) 0.1523
Values are mean+SD or n (%) and compared with independent samples t-test or Fisher exact tests, respectively.
ACE, angiotensin-converting enzyme; ARB, angiotensin receptorblocker;BMI, body mass index;BP,blood pressure; CABG,coronaryartery bypass grafting; CAD,coronaryartery
disease; COPD, chronic obstructive pulmonary disease; CRI, chronic renal insufﬁciency; CVA, cerebral vascular accident; DM, diabetes mellitus; HF, heart failure; ICD, implantable
cardiac deﬁbrillator; JVP, jugular venous pressure; MI, myocardial infarction.
................................................................ ...............................................................
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Table 2 Prediction of pneumonia diagnoses (n 5 155 events) from signs, physician-estimated probability of pneumonia
(visual analogue scale), and procalcitonin concentration
Predictor Univariable model results Multivariable model results
OR 95%CI x
2 P-value AUC OR 95% CI x
2 P-value AUC
Model with individual variables
Temperature (8C) 2.2 1.9–2.5 124.1 ,0.0001 0.709 1.8 1.5–2.1 45.5 ,0.0001
PCT (log, ng/mL) 1.9 1.7–2.1 106.8 ,0.0001 0.723 1.6 1.4–1.9 38.7 ,0.0001
Cough (yes) 6.7 4.0–11.4 76.2 ,0.0001 0.668 4.7 2.6–8.5 25.5 ,0.0001
Past pneumonia (yes) 4.7 3.3–6.7 65.0 ,0.0001 0.647 3.7 2.4–5.7 34.5 ,0.0001
Heart rate (b.p.m.) 1.7 1.4–2.1 31.4 ,0.0001 0.651 1.6 1.2–2.1 12.8 0.0004
Rales (yes) 1.9 1.4–2.7 15.0 0.0001 0.578 1.5 1.0–2.3 3.3 0.0696
Pulse oximetry (log,%) 0.9 0.8–0.9 12.2 0.0005 0.659 1.0 0.9–1.1 0.6 0.4397
Diastolic BP (mmHg) 0.7 0.6–0.9 11.2 0.0008 0.580 0.7 0.5–0.9 7.2 0.0073
Model with summary variable
VAS pneumonia (%) 5.5 4.4–6.9 265.5 ,0.0001 0.850 4.7 3.7–6.0 163.0 ,0.0001
PCT (log, ng/mL) 1.9 1.7–2.1 106.8 ,0.0001 0.723 1.4 1.3–1.7 27.2 ,0.0001
Area under the curve (AUC) is bootstrap corrected for multivariable models.
BP, blood pressure; CI, conﬁdence interval; OR, odds ratio; PCT, procalcitonin; VAS, visual analogue scale.
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and survival in patients presenting with
acute heart failure
Unadjusted data showed that patients treated with antibiotics had
higher 90-day all-cause mortality than patients not treated (P ¼
0.032). After adjustment of covariates to control for group differ-
ences with respect to expected outcome, overall survival rates for
AHF patients were not different whether or not they were treated
with antibiotics (P ¼ 0.583, Figure 4A). However, dividing the AHF
patients into subgroups based on PCT concentration revealed sur-
vival differences between those treated or not treated with anti-
biotics. Patients with a PCT concentration .0.21 ng/mL had
signiﬁcantly worse survival if not treated with antibiotics (P ¼
0.046, Figure 4B). For AHF patients with PCT concentrations
between 0.05 and 0.21 ng/mL, antibiotic treatment did not affect
survival (P ¼ 0.36, Figure 4C). AHF patients with low PCT values
(,0.05 ng/mL, Figure 4D) had an increased mortality if they were
treated with antibiotics (P ¼ 0.049).
The utility of procalcitonin combined
with mid-regional pro atrial natriuretic
peptide in the differential diagnosis of
dyspneoa
Figure 5 illustrates schematically how the combination of mid-
regional pro atrial natriuretic peptide (MR-proANP) [or brain
natriuretic peptide (BNP)] and PCT can be used to diagnose
acutely dyspnoeic patients with AHF and/or pneumonia: a
PCT . 0.1 ng/mL together with an MR-proANP .350 pmol/L
deﬁned community-acquired pneumonia occurring with concomi-
tant AHF; a PCT . 0.1 ng/mL with an MR-proANP ,100 pmol/L
deﬁned community-acquired pneumonia alone, while an
MR-proANP .350 pmol/L and a PCT ,0.1 ng/mL deﬁned HF
alone. A similar algorithm can be deduced for BNP. The median
and IQR for PCT and MR-proANP values in the four subgroups
are listed in the legend of Figure 5.
Discussion
Differentiating the diagnosis of pneumonia from that of HF can be
difﬁcult, and disastrous consequences may occur from a mistake.
3,4
Moreover, detecting superimposed pneumonia in patients
Figure 2 Distribution of patients based on physician-estimated
probability of pneumonia (low, medium, and high) and how this
distribution would shift if a procalcitonin (PCT) concentration
of ,0.25 ng/mL was adopted as a model to rule out pneumonia.
Figure 3 Kaplan–Meier plot of procalcitonin (PCT) quintiles
for patients diagnosed with acute heart failure (AHF). PCT was
signiﬁcantly associated with 90-day all-cause mortality for patients
diagnosed with AHF (Cox regression, x
2 9.2, P ¼ 0.0024).
Figure 1 Receiver operating characteristic (ROC) curves for
the diagnosis of pneumonia (n ¼ 155 events), comparing procal-
citonin (PCT), the multivariable model including clinical signs, as
well as the clinical signs model plus PCT.
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and therefore non-speciﬁc physical exam and chest X-ray abnor-
malities. This can also lead to great morbidity and mortality.
3,4
This study serves to highlight the difﬁculty clinicians face in diagnos-
ing pneumonia in patients presenting with AHF.
In HF patients it is obviously important to identify those with the
highest risk in order to improve outcome. Superimposed pulmon-
ary disease has been shown to lead to increased morbidity and
mortality in HF patients. Iverson and colleagues
14 have shown a
clear link between lung function and outcome in HF patients by
demonstrating the prognostic importance of spirometric variables,
in addition to known risk factors, including self-reported COPD.
These authors posit the knowledge that patients who have
COPD may reduce the risk of overdosing diuretics due to
misinterpretation of the primary underlying cause of dyspnoea.
A similar argument can be made for those with pneumonia in our
study.
Our results suggest that PCT provides additive diagnostic infor-
mation in patients presenting with shortness of breath; models
using PCT were robust when clinical uncertainty existed. Further-
more, our data speak to the potential utility of PCT in predicting
clinical beneﬁt from antibiotic treatment. Patients with a PCT
concentration .0.21 ng/mL had signiﬁcantly worse survival if
not treated with antibiotics, and those with PCT values
,0.05 ng/mL had an increased mortality if they were treated
with antibiotics, suggesting that the risks of antibiotic administra-
tion may outweigh the beneﬁts in this group. Taken together,
these data suggest that the incorporation of PCT into the decision
Figure 4 Kaplan–Meier plot for antibiotic treatment and all-cause mortality within 90 days for patients with acute heart failure (A; all AHF
patients) and subgrouped by procalcitonin (PCT) quintiles: PCT . 0.21 ng/mL (B; highest quintile, P ¼ 0.049), between 0.05 and 0.21 (C;
P ¼ 0.36, summarizing quintiles 2–4), and ,0.05 ng/mL (D; lowest quintile, P ¼ 0.046). Survival rate is adjusted for covariates; see Methods.
Figure 5 Median procalcitonin (PCT) and mid-regional pro atrial natriuretic peptide (MR-proANP) concentrations (left), as well as median
PCT and brain natriuretic peptide (BNP) concentrations (right) for patients with acute heart failure (AHF) alone, pneumonia alone, AHF and
pneumonia, and those without either condition. The median and interquartile range (IQR) for PCT (in ng/mL) in the four subgroups were as
follows: no AHF, no pneumonia 0.06 (0.04–0.09); pneumonia, no AHF 0.23 (0.07–0.92); AHF, no pneumonia 0.09 (0.06–0.16); and AHF and
pneumonia 0.14 (0.09–0.26). For MR-proANP (in pmol/L): no AHF, no pneumonia 84 (47–183); pneumonia, no AHF 141 (62–240); AHF, no
pneumonia 417 (277–620); and AHF and pneumonia 398 (279–635). For BNP (in ng/mL): no AHF, no pneumonia 50 (20–166); pneumonia, no
AHF 122 (37–292); AHF, no pneumonia 766 (409–1461); and AHF and pneumonia 400 (210–857).
A. Maisel et al. 284to administer antibiotic therapy to patients presenting with AHF
may impact survival.
Our data also demonstrate that combining PCT with
MR-proANP, which was reported in this population to aid in the
diagnosis of AHF,
7 holds promise for the categorization of
acutely dyspnoeic patients into three groups mandating early
therapy, speciﬁcally those with either HF alone, pneumonia
alone, or both in combination. Figure 5 shows the median PCT
and MR-proANP/BNP concentrations in all patients, grouped by
the presence or absence of pneumonia and AHF, and underscores
how multiple biomarkers may be combined to assist in the diagno-
sis of clinically challenging overlapping disease states. Gheorghiade
et al. and colleagues have previously proposed that a wide range of
clinical and laboratory markers be used in combination to assess
and grade congestion in acute HF more optimally in order to
better direct management.
15 It could be argued that improved
grading strategies, making optimal use of serum biomarkers,
would be equally if not more important in the acute management
of the undifferentiated dyspnoea that presents to EDs.
Limitations
There are several limitations of our study. Antibiotic treatment was
neither randomized nor standardized in terms of type and dosage,
and the analysis was post-hoc and not pre-speciﬁed. C-reactive
protein measurements, which are frequently used in the differential
diagnosis of HF vs. pneumonia, were not included in the analysis.
Due to the lack of randomization, it is probable that sicker patients
were also more likely to receive antibiotics, which probably
explains the observed difference in risk of death. The number of
patients ultimately diagnosed with both pneumonia and AHF was
low, possibly reﬂecting our broad inclusion criteria of undifferenti-
ated dyspnoea, consistent with the primary endpoint of the trial.
This might also reﬂect a pre-selection bias of the on-site cardiolo-
gist responsible for making the initial assessment and therefore
some cases of pneumonia might have escaped detection. This
may also explain the slightly worse diagnostic performance in
patients with concurrent AHF.
Hence our conclusions are exploratory and need validation in a
randomized controlled trial. The rationale for carrying out this ana-
lysis in the large BACH dyspnoea trial was to evaluate whether
PCT could aid in the decision to initiate antibiotics in patients
with a primary diagnosis of AHF, where pneumonia occurs as a
relevant but possibly less apparent co-morbidity. If this is proven,
a logical next phase might then be a study treating according to
biomarker stratiﬁcation.
Another potential limitation is that the conﬁrmation of diagnosis
was performed by two independent cardiologists who made the
ﬁnal diagnosis. This method of diagnosis has the potential for
bias of underreporting when two specialists from the same discip-
line are making the ﬁnal diagnosis.
Clinical implications
This study extends the knowledge from previous work evaluating
the clinical utility of PCT in the diagnosis and management of
patients with suspected community-acquired pneumonia in the
setting where AHF is also a possibility. There is a strong likelihood
that PCT levels will help guide diagnostic therapeutic decisions
with antibiotics. This needs to be tested in a large randomized
interventional trial.
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